Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian K Link

Showing results (71-80 of 231) with videos related to

Pageof 24
Sort By:
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 15, 2006
Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphomaBrian K Link, Zuhair K Ballas, Daniel Weisdorf, et al.
Blood Advances|April 7, 2022
Single-cell analysis of Sézary syndrome reveals novel markers and shifting gene profiles associated with treatmentNicholas Borcherding, Kevin J Severson, Nicholas Henderson, et al.
Cancer|March 27, 2014
The use and effectiveness of rituximab maintenance in patients with follicular lymphoma diagnosed between 2004 and 2007 in the United StatesLoretta J Nastoupil, Rajni Sinha, Michelle Byrtek, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2008
A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphomaEmilian Racila, Brian K Link, Wen-Kai Weng, et al.
Cancer|March 22, 2012
Racial differences in presentation and management of follicular non-Hodgkin lymphoma in the United States: report from the National LymphoCare StudyChadi Nabhan, Michelle Byrtek, Michael D Taylor, et al.
Blood|October 8, 2015
Intravenous immune globulin and thromboembolic adverse events in patients with hematologic malignancyEric M Ammann, Michael P Jones, Brian K Link, et al.
British Journal of Haematology|January 6, 2016
Outcomes following watchful waiting for stage II-IV follicular lymphoma patients in the modern eraLoretta J Nastoupil, Rajni Sinha, Michelle Byrtek, et al.
British Journal of Haematology|April 9, 2015
Disease characteristics, treatment patterns, prognosis, outcomes and lymphoma-related mortality in elderly follicular lymphoma in the United StatesChadi Nabhan, Michelle Byrtek, Ashish Rai, et al.
American Journal of Hematology|April 7, 2017
Associations between elevated pre-treatment serum cytokines and peripheral blood cellular markers of immunosuppression in patients with lymphomaMoritz Binder, Megan M O'Byrne, Matthew J Maurer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2021
Impact of Organ Function-Based Clinical Trial Eligibility Criteria in Patients With Diffuse Large B-Cell Lymphoma: Who Gets Left Behind?Arushi Khurana, Raphael Mwangi, Grzegorz S Nowakowski, et al.
Pageof 24

Showing results (71-80 of 231) with videos related to

Sort By:
Pageof 24
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 15, 2006
Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphomaBrian K Link, Zuhair K Ballas, Daniel Weisdorf, et al.
Blood Advances|April 7, 2022
Single-cell analysis of Sézary syndrome reveals novel markers and shifting gene profiles associated with treatmentNicholas Borcherding, Kevin J Severson, Nicholas Henderson, et al.
Cancer|March 27, 2014
The use and effectiveness of rituximab maintenance in patients with follicular lymphoma diagnosed between 2004 and 2007 in the United StatesLoretta J Nastoupil, Rajni Sinha, Michelle Byrtek, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2008
A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphomaEmilian Racila, Brian K Link, Wen-Kai Weng, et al.
Cancer|March 22, 2012
Racial differences in presentation and management of follicular non-Hodgkin lymphoma in the United States: report from the National LymphoCare StudyChadi Nabhan, Michelle Byrtek, Michael D Taylor, et al.
Blood|October 8, 2015
Intravenous immune globulin and thromboembolic adverse events in patients with hematologic malignancyEric M Ammann, Michael P Jones, Brian K Link, et al.
British Journal of Haematology|January 6, 2016
Outcomes following watchful waiting for stage II-IV follicular lymphoma patients in the modern eraLoretta J Nastoupil, Rajni Sinha, Michelle Byrtek, et al.
British Journal of Haematology|April 9, 2015
Disease characteristics, treatment patterns, prognosis, outcomes and lymphoma-related mortality in elderly follicular lymphoma in the United StatesChadi Nabhan, Michelle Byrtek, Ashish Rai, et al.
American Journal of Hematology|April 7, 2017
Associations between elevated pre-treatment serum cytokines and peripheral blood cellular markers of immunosuppression in patients with lymphomaMoritz Binder, Megan M O'Byrne, Matthew J Maurer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2021
Impact of Organ Function-Based Clinical Trial Eligibility Criteria in Patients With Diffuse Large B-Cell Lymphoma: Who Gets Left Behind?Arushi Khurana, Raphael Mwangi, Grzegorz S Nowakowski, et al.
Pageof 24